Compare BTQ & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTQ | CDNA |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.8M | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | BTQ | CDNA |
|---|---|---|
| Price | $5.49 | $19.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $10.00 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 3.1M | 768.6K |
| Earning Date | 03-25-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | $405,988.00 | ★ $357,998,000.00 |
| Revenue This Year | $100.70 | $14.11 |
| Revenue Next Year | $669.96 | $11.75 |
| P/E Ratio | ★ N/A | $16.03 |
| Revenue Growth | ★ 35.72 | 14.46 |
| 52 Week Low | $0.95 | $10.96 |
| 52 Week High | $16.00 | $25.95 |
| Indicator | BTQ | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.88 |
| Support Level | N/A | $19.01 |
| Resistance Level | N/A | $20.61 |
| Average True Range (ATR) | 0.00 | 0.80 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 0.00 | 25.75 |
BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. Its products include PQScale, Keelung, Kenting, and Qbyte. PQScale is a novel scaling technique for post-quantum cryptographic primitives. Keelung is a zero-knowledge toolkit for fast, private, and secure applications. Kenting provides acceleration for NIST-compliant post-quantum cryptography, post-quantum zk-SNARKs, and eco-friendly mining hardware, and Qbyte is a quantum risk calculator. Geographically, the company derives maximum revenue from Canada, and also has a presence in Taiwan, and Australia.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.